119 related articles for article (PubMed ID: 35575146)
1. Toxicity associated with high-dose intravenous methotrexate for hematological malignancies.
Wight J; Ku M; Garwood M; Carradice D; Lasica M; Keamy L; Hawkes EA; Grigg A
Leuk Lymphoma; 2022 Oct; 63(10):2375-2382. PubMed ID: 35575146
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
3. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
Zhao M; Liang L; Ji L; Chen D; Zhang Y; Zhu Y; Ongaro A
Pharmacogenomics; 2016 Jun; 17(9):1005-17. PubMed ID: 27270164
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S; Fujiwara SI; Murahashi R; Nakashima H; Matsuoka S; Ikeda T; Toda Y; Ito S; Ban T; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Kanda Y
Int J Hematol; 2021 Jul; 114(1):79-84. PubMed ID: 33743109
[TBL] [Abstract][Full Text] [Related]
6. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.
Mandal P; Samaddar S; Chandra J; Parakh N; Goel M
Indian J Hematol Blood Transfus; 2020 Jul; 36(3):498-504. PubMed ID: 32647424
[TBL] [Abstract][Full Text] [Related]
8. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
9. Hypoalbuminemia and not undernutrition predicts high-dose methotrexate-induced nephrotoxicity in children with acute lymphoblastic leukemia in resource-constrained centers.
Khera S; Sharma G; Negi V; Shaw SC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29738. PubMed ID: 35451162
[TBL] [Abstract][Full Text] [Related]
10. Renal Function and Plasma Methotrexate Concentrations Predict Toxicities in Adults Receiving High-Dose Methotrexate.
Yang Y; Wang X; Tian J; Wang Z
Med Sci Monit; 2018 Oct; 24():7719-7726. PubMed ID: 30369593
[TBL] [Abstract][Full Text] [Related]
11. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
13. The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients.
Traivaree C; Likasitthananon N; Monsereenusorn C; Rujkijyanont P
Cancer Manag Res; 2018; 10():4471-4478. PubMed ID: 30349379
[TBL] [Abstract][Full Text] [Related]
14. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
[TBL] [Abstract][Full Text] [Related]
15. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate in ICU patients: a retrospective study.
Valade S; Mariotte E; Azoulay E; Darmon M
Ann Intensive Care; 2020 Jun; 10(1):81. PubMed ID: 32535662
[TBL] [Abstract][Full Text] [Related]
17. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.
May J; Carson KR; Butler S; Liu W; Bartlett NL; Wagner-Johnston ND
Leuk Lymphoma; 2014 Jun; 55(6):1345-9. PubMed ID: 24004183
[TBL] [Abstract][Full Text] [Related]
18. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
19. Crystalline Nephropathy With High-Dose Methotrexate in a Patient With Primary CNS Lymphoma: A Case Report.
Sami FL; Hammo H; Athavale A
Cureus; 2022 Jun; 14(6):e26052. PubMed ID: 35865443
[TBL] [Abstract][Full Text] [Related]
20. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]